Change in sedative burden after dementia onset using difference-in-difference estimations

PloS One
Young-Mi AhJu-Yeun Lee

Abstract

Sedative agents are avoided in older adults because of potential risks including cognitive impairment, fall, frailty, and mortality. However, no studies addressing both prediagnostic and postdiagnostic period of dementia have evaluated sedative agent usage over an extended period. To describe a longitudinal change in sedative medication use before and after the diagnosis with dementia over 10 years compared to patients without dementia. We conducted a retrospective cohort study using longitudinal claims data for senior national health insurance beneficiaries. After 1:4 propensity score matching, 54,165 older patients (≥60 years) were included. Difference-in-difference (DID) of sedative burden and use of sedative agents pre- and post-dementia diagnosis were estimated, and compared to those of patients without dementia. The yearly average daily sedative load (adSL) for each individual was calculated after applying duration, dose, and sedative score of medications from the sedative load model. The medication use for each sedative category was calculated using the defined daily dose (DDD) per 1000 patient-days. The adSL in patients with dementia was consistently high before and after diagnosis and significantly increased after diag...Continue Reading

References

May 16, 1998·Biological Psychiatry·D F KripkeL Garfinkel
Sep 11, 2002·International Journal of Geriatric Psychiatry·T LinjakumpuR Isoaho
Jun 6, 2003·International Journal of Geriatric Psychiatry·T LinjakumpuR Isoaho
Oct 28, 2004·The Annals of Pharmacotherapy·Tarja A LinjakumpuRaimo E Isoaho
Apr 25, 2007·Archives of Internal Medicine·Sarah N HilmerDarrell R Abernethy
Feb 12, 2009·Journal of the American Geriatrics Society·Rollin M WrightUNKNOWN Health, Aging and Body Composition Study
Oct 1, 2007·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Nathan HerrmannPaul G Lysy
Feb 22, 2011·The American Journal of Geriatric Pharmacotherapy·Heidi T TaipaleJ Simon Bell
Oct 1, 2011·BMC Geriatrics·Carole ParsonsClaire Goodman
Aug 2, 2012·Fundamental & Clinical Pharmacology·Danijela GnjidicBell J S
Aug 19, 2014·Journal of the American Medical Directors Association·Adelaide de MauleonUNKNOWN RightTimePlaceCare Consortium
Sep 27, 2014·Health & Social Care in the Community·Arthorn RiewpaiboonE Pamela Wright
Dec 2, 2014·Journal of the American Medical Directors Association·Jure PeklarMitja Kos
Oct 9, 2015·Journal of the American Geriatrics Society·UNKNOWN By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel
May 20, 2016·Clinical Interventions in Aging·Nibu Parameswaran NairLuke R Bereznicki
Sep 2, 2016·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Anders WimoMartin Prince
Dec 26, 2016·Neuroepidemiology·Md Mohaimenul IslamSyed-Abdul Shabbir
Dec 31, 2016·Journal of Alzheimer's Disease : JAD·Ane NørgaardGunhild Waldemar
Aug 24, 2017·BMC Psychiatry·Soo-Hee HwangTae Hyun Kim
Nov 1, 2017·International Journal of Clinical Pharmacy·Elodie Jean-BartChristelle Mouchoux
Mar 3, 2019·Journal of the American Medical Directors Association·Emilia SchwertnerDorota Religa

❮ Previous
Next ❯

Methods Mentioned

BETA
sedation

Software Mentioned

SAS
STATA

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Ärztliche Wochenschrift
F FRANZEN
Medizinische Monatsschrift für Pharmazeuten
S Shnädelbach
The Medical and Physical Journal
Robert Kinglake
© 2021 Meta ULC. All rights reserved